Half-year statement of Ipsen’s liquidity contract

Paris (France), 8 January 2010 - As of December 31, 2009, as per the liquidity contract implemented with Natexis Securities, the following assets appeared on the liquidity account:

- 37,464 shares
- 2,872,138.75€

As a reminder, as of the last half-year statement, the following assets appeared on the liquidity account:

- 76,776 shares
- 1,458,292.82 €

About Ipsen
Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about €183 million, close to 19% of consolidated sales, which amounted to €971 million while total revenues exceeded €1 billion. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the “Service de Règlement Différé” (“SRD”) and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

For further information

Didier Véron
Director, Public Affairs and Corporate Communications
Tél.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
e-mail: didier.veron@ipsen.com

David Schilansky
Investor Relations and Financial Officer
Tél.: +33 (0)1 58 33 51 30
Fax: +33 (0)1 58 33 50 63
e-mail: david.schilansky@ipsen.com

Pierre Kemula
Investor Relations Manager
Tél.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
e-mail: pierre.kemula@ipsen.com